Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA sequences that bind to specific messenger RNA (mRNA) targets through Watson-Crick base pairing, enabling precise control of protein production. This technology has emerged as a powerful platform for treating neurodegenerative diseases, with tofersen (Qalsody) becoming the first FDA-approved ASO for a neurodegenerative disease in 2023. By directly modulating RNA, ASOs can reduce toxic protein levels, restore normal splicing patterns, and increase expression of protective protein variants—offering a complementary approach to antibodies and small molecules.
ASOs employ two primary mechanisms:
- ASO binds to complementary mRNA
- Forms RNA-DNA hybrid recognized by RNase H1
- RNase H cleaves the RNA strand
- Result: Reduced protein production from target mRNA
- ASO binds to pre-mRNA at specific sites
- Masks or reveals splice sites
- Alters exon inclusion/skipping
- Result: Different protein isoforms produced
- Steric blockade of translation initiation
- Interference with RNA processing
- miRNA sponges (specific ASO designs)
Tofersen (Qalsody) - FDA Approved 2023
- Target: SOD1 mRNA
- Indication: SOD1-associated Amyotrophic Lateral Sclerosis (ALS)
- Manufacturer: Biogen/Ionis
- Efficacy: 36% reduction in SOD1 protein, positive trend in clinical endpoints
- Status: First ASO approved for neurodegenerative disease
Nusinersen (Spinraza)
- Target: SMN2 pre-mRNA
- Indication: Spinal Muscular Atrophy (SMA)
- Manufacturer: Biogen/Ionis
- Efficacy: Landmark approval, dramatically improved outcomes in infants and children
- Note: While SMA is not classic neurodegeneration, validates platform
| Drug |
Company |
Target |
Indication |
Phase |
| IONIS-MAPTRx |
Ionis/Biogen |
MAPT mRNA |
Alzheimer's disease |
Phase 1/2 |
| IONIS-HTTRx |
Ionis/Roche |
HTT mRNA |
Huntington's disease |
Phase 1/2 |
| IONIS-C9orf72 |
Ionis/Biogen |
C9orf72 RNA |
ALS/FTD |
Phase 1/2 |
| WVE-004 |
Wave Life Sciences |
C9orf72 |
ALS/FTD |
Phase 1b |
| IONIS-TIP4P |
Ionis |
4R tau |
PSP |
Preclinical |
IONIS-MAPTRx (BIIB080)
- Reduces production of all tau isoforms
- Phase 1/2 showed dose-dependent reduction in cerebrospinal fluid tau
- Potential for both Alzheimer's and 4R tauopathies (PSP, CBD)
- Partnered with Biogen
IONIS-HTTRx (RO7234292)
- Lowers mutant huntingtin protein
- Phase 1/2 showed 40-60% reduction in CSF huntingtin
- First demonstration of huntingtin lowering in humans
- Partnered with Roche
C9orf72 Programs
- Target repeat-containing RNA from expanded C9orf72 gene
- Most common genetic cause of ALS and FTD
- Multiple programs in early development
- Direct binding to specific RNA sequences
- Can target any gene with known sequence
- Predictable dose-response relationship
- Systemically administered ASOs reach the brain and spinal cord
- Distribution to multiple brain regions
- Particularly good reach to spinal cord (relevant for ALS, SMA)
- Protein levels return to baseline after stopping treatment
- Allows treatment interruption if needed
- Useful for safety assessment
- ASO chemistry can be optimized for each target
- Gapmer design for RNase H activity
- Steric-blocking ASOs for splicing modulation
- Multiple approvals in neurological diseases
- Established regulatory frameworks
- Clear development pathways
- Sequences with partial complementarity may be affected
- Requires careful sequence optimization
- Careful safety monitoring required
- Most ASOs require monthly to quarterly administration
- Long-term treatment burden
- Patient compliance considerations
- Distribution largely to glial cells
- Limited neuronal uptake
- May require engineering for specific populations
- Liver function monitoring required
- Platelet count monitoring
- Potential for thrombocytopenia
- Annual treatment costs exceed $100,000
- Similar to antibody therapies
- Long-term financial burden
¶ Chemistry and Design
- Phosphorothioate backbone
- First clinical ASOs (Fomivirsen)
- Higher nuclease resistance than natural DNA
- 2'-O-methyl or 2'-O-methoxyethyl modifications
- Improved affinity and stability
- Reduced toxicity
- Gapmer design: 2'-modified wings, DNA gap
- Maximizes RNase H activity
- Currently most advanced in clinic
- Defined stereochemistry at each chiral center
- Improved potency and safety
- Used by Wave Life Sciences
- Conjugates for receptor-mediated uptake
- Brain-penetrant ASOs
- Cell-type specific targeting
- ASO + antibody therapy
- ASO + small molecule
- Multiple ASOs targeting different pathways
- TDP-43 proteinopathies
- RNA foci in repeat expansion diseases
- Non-coding RNAs